News

Coramitug is a potential best-in-class amyloid depleter antibody for the treatment of ATTR amyloidosis with cardiomyopathy1-3Coramitug is being evaluated by Novo…

AbstractBackgroundLarge-scale, nationwide data for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) in Japan are limited.ObjectivesThis multicenter…

AbstractTransthyretin (TTR) amyloidosis is a protein misfolding disease characterized by amyloid fibril deposition in vital organs, leading to cardiomyopathy (ATTR-…

AbstractWild-type transthyretin cardiac amyloidosis (ATTRwt-CM) is increasingly recognized as an underdiagnosed cause of heart failure with preserved ejection…

Systemic amyloidoses represent a group of rare diseases that are often underdiagnosed due to their multifaceted symptomatic picture. In these multisystem diseases,…

Amyloid light chain (AL) cardiomyopathy (AL-CM) is a highly aggressive disease with high early mortality without prompt and effective treatment; however, its low…

Webinar Session: Wednesday, April 22nd at 6 PM (ET) Zoom Meeting(These sessions will not be recorded due to patient involvement and HIPAA laws)To Register …

AbstractBackgroundCardiac biomarker complete response (CR) is a new concept in amyloid light chain (AL) cardiac amyloidosis (CA).ObjectivesThe aim of this study was…

AbstractBackground and AimsEarly detection is important given the availability of new disease-modifying therapies and the high prevalence of transthyretin amyloid…

The biomarker MR-proADM improves risk prediction in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) and is associated with greater disease…